5 Key Takeaways

• 1

  The GUARD trial demonstrated that intravitreal methotrexate 0.8% (ADX-2191) reduces postoperative complications in PVR surgery.

• 2

  Patients receiving ADX-2191 had significantly lower rates of hypotony and cystoid macular edema compared to historical controls.

• 3

  The trial reported a 24% reoperation rate in the ADX-2191 group versus 39% in controls, indicating a potential benefit.

• 4

  The most common adverse event with ADX-2191 was mild to moderate punctate keratitis, occurring in 16% of cases.

• 5

  Routine surgical care with ADX-2191 showed numerical superiority in reducing postoperative adverse events.